Most-Upgraded StocksMost-UpgradedNASDAQ:BIIB Biogen (BIIB) Stock Price, News & Analysis $188.18 -4.06 (-2.11%) As of 02:13 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biogen Stock (NASDAQ:BIIB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biogen alerts:Sign Up Key Stats Today's Range$191.67▼$195.2850-Day Range$172.34▼$204.5352-Week Range$121.05▼$205.97Volume841,497 shsAverage Volume1.08 million shsMarket Capitalization$27.78 billionP/E Ratio20.37Dividend YieldN/APrice Target$215.81Consensus RatingModerate Buy Company Overview Biogen Inc. is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets. The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders. Biogen has also been active in the Alzheimer's field through collaborations with Eisai, bringing antibodies targeting amyloid pathology to market. In addition, Biogen has worked with partners on treatments for spinal muscular atrophy and other rare diseases, reflecting a mix of proprietary development and co-commercialization arrangements. Biogen invests heavily in research and development, maintaining clinical-stage programs across a range of neuroscience indications and pursuing both small- and large-molecule approaches. The company operates through a combination of internal discovery, external collaborations, licensing deals and strategic acquisitions to expand its pipeline and commercial reach. Biogen is governed by an executive leadership team and a board of directors responsible for setting corporate strategy and overseeing its global operations.AI Generated. May Contain Errors. Read More Biogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreBIIB MarketRank™: Biogen scored higher than 71% of companies evaluated by MarketBeat, and ranked 274th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingBiogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.52, and is based on 1 strong buy rating, 14 buy ratings, 13 hold ratings, and 1 sell rating.Upside PotentialBiogen has a consensus price target of $215.81, representing about 14.5% upside from its current price of $188.42.Amount of Analyst CoverageBiogen has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biogen's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth16.78% Earnings GrowthEarnings for Biogen are expected to grow by 16.78% in the coming year, from $14.18 to $16.56 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biogen is 20.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.29.Price to Earnings Ratio vs. SectorThe P/E ratio of Biogen is 20.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.14.Price to Earnings Growth RatioBiogen has a PEG Ratio of 1.73. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBiogen has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biogen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.21% of the float of Biogen has been sold short.Short Interest Ratio / Days to CoverBiogen has a short interest ratio ("days to cover") of 4.21.Change versus previous monthShort interest in Biogen has recently increased by 5.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiogen does not currently pay a dividend.Dividend GrowthBiogen does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.33 News SentimentBiogen has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Biogen this week, compared to 14 articles on an average week.Search InterestOnly 16 people have searched for BIIB on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows7 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biogen insiders have not sold or bought any company stock.Percentage Held by Insiders0.25% of the stock of Biogen is held by insiders.Percentage Held by Institutions87.93% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biogen's insider trading history. Receive BIIB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIIB Stock News HeadlinesIs COMPASS Pathways (CMPS) Quietly Recalibrating Its Commercialization Strategy With This Board Appointment?June 2 at 8:42 AM | finance.yahoo.comBiogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration PipelineJune 2 at 8:42 AM | finance.yahoo.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 2 at 1:00 AM | Porter & Company (Ad)Sobi to present new data on pegcetacoplan at ERA 2026June 1 at 8:47 AM | finance.yahoo.comBiogen, UCB lupus drug dapirolizumab pegol meets phase 3 goalJune 1 at 3:46 AM | seekingalpha.comUCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus ErythematosusJune 1 at 3:46 AM | finance.yahoo.comMarketBeat Week in Review – 05/18 - 05/22 (BIIB)Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports...May 23, 2026 | marketbeat.comBiogen Stock Slides After Trial Miss, But Analysts Stay BullishBiogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock...May 22, 2026 | marketbeat.comSee More Headlines BIIB Stock Analysis - Frequently Asked Questions How have BIIB shares performed this year? Biogen's stock was trading at $175.99 at the beginning of 2026. Since then, BIIB stock has increased by 7.1% and is now trading at $188.4150. How were Biogen's earnings last quarter? Biogen Inc. (NASDAQ:BIIB) announced its quarterly earnings results on Wednesday, April, 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.95 by $0.62. The company's quarterly revenue was up 1.9% on a year-over-year basis. Read the conference call transcript. Does Biogen have any subsidiaries? The following companies are subsidiaries of Biogen: Nightstar Therapeutics plc, Convergence Pharmaceuticals, TYSABRI, Stromedix Inc., Panima Pharmaceuticals AG, Syntonix Pharmaceuticals Inc., Fumapharm, and more. Who are Biogen's major shareholders? Biogen's top institutional shareholders include Bank of America Corp DE (0.78%), Dimensional Fund Advisors LP (0.73%), Pictet Asset Management Holding SA (0.62%) and Amundi (0.54%). Insiders that own company stock include Eric K Rowinsky, Nicole Murphy, Stephen A Sherwin, Stephen A Sherwin, Stephen A Sherwin, Priya Singhal and Rachid Izzar. View institutional ownership trends. How do I buy shares of Biogen? Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biogen investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Intel (INTC). Company Calendar Last Earnings4/29/2026Today6/02/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 BIIB's financial health is in the Green zone, according to TradeSmith. BIIB has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:BIIB CIK875045 Webwww.biogen.com Phone(617) 679-2000Fax617-679-2617Employees7,500Year Founded1978Price Target and Rating Average Price Target for Biogen$215.81 High Price Target$300.00 Low Price Target$150.00 Potential Upside/Downside+14.7%Consensus RatingModerate Buy Rating Score (0-4)2.52 Research Coverage29 Analysts Profitability EPS (Trailing Twelve Months)$9.32 Trailing P/E Ratio20.37 Forward P/E Ratio13.27 P/E Growth1.73Net Income$1.29 billion Net Margins13.81% Pretax Margin16.33% Return on Equity12.83% Return on Assets8.01% Debt Debt-to-Equity Ratio0.34 Current Ratio3.06 Quick Ratio2.41 Sales & Book Value Annual Sales$9.89 billion Price / Sales2.81 Cash Flow$21.73 per share Price / Cash Flow8.66 Book Value$124.45 per share Price / Book1.51Miscellaneous Outstanding Shares147,640,000Free Float147,268,000Market Cap$27.78 billion OptionableOptionable Beta0.20 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:BIIB) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersThe Rare Earth Shift Few Saw ComingRare earth elements sit inside modern defense systems, high-performance magnets, and advanced electronics - ye...i2i Marketing Group, LLC | SponsoredBNZI posted 169 percent revenue growth - is a turnaround formingBanzai International (NASDAQ: BNZI) reported full-year 2025 revenue of $12.2 million, up 169% year-over-year, ...Huge Alerts | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayOctober 14th, 2025, CNBC quietly published an interview with BlackRock's CEO, who went on live television and ...Decentralized Masters | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
